Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Cuts Spending in Q2 as Revenue Plunges 27 Percent

NEW YORK (GenomeWeb News) — CombiMatrix today said that second-quarter revenue plunged 27 percent as R&D spending was cut nearly in half and net loss widened 5 percent.
 
Total receipts for the three months ended June 30 decreased to $1.3 million from $1.8 million during the same period last year.
 
Product sales declined 60 percent to $458,000; government contract revenue rose 20 percent to $680,000; and service revenue was up more than 230 percent to $199,000 from $60,000.
 
R&D spending fell to $1.1 million from $2.2 million. The numbers include non-cash stock compensation expense of $144,000 for the second quarter of 2007 and $193,000 for the second quarter of 2006.
 
Net loss increased to $3.6 million from $3.4 million year over year.
 
CombiMatrix had around $12.8 million in cash, equivalents, and short term investments as of June 30.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.